UNSPSC 51171716: Lidamidine

This classification denotes an antidiarrheal agent with the molecular formula C11H16N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q8X04W8418, chemically known as urea, n-(2,6-dimethylphenyl)-n-(imino(methylamino)methyl)- but generally known as lidamidine, which bears US NIH Compound Identifier 47510. European Medicines Agency schedules Lidamidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08504MIG.

UNSPSC 51171716 Lidamidine is a Commodity code representing pharmaceutical active ingredients and finished drug products procured by state and local health and human services agencies. Recent state and local opportunities under this code span drug testing services, pharmaceutical benefit program redesign, and multi-source generic pharmaceutical distribution—reflecting the breadth of how state agencies source both specialized pharmaceutical services and commodity pharmaceuticals for correctional, Medicaid, and employee health programs. Issuing bodies soliciting under the code include county correctional departments, state health and human services commissions, and multi-state cooperative purchasing alliances administering contracts on behalf of state agencies and local government facilities. The work ranges from specialized clinical laboratory services (specimen collection, immunoassay screening, and confirmatory testing) to large-volume generic drug procurement and supply chain management through established pharmaceutical wholesalers.

Geographic activity centers on Texas and Minnesota, with multi-state scope in Minnesota's cooperative purchasing vehicle. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services due July 23, 2026, seeking a vendor to staff two collection sites in Plano and McKinney, operate an Interactive Voice Response system for randomized testing notifications, and perform immunoassay and confirmatory testing (LC/MS/MS or GC/MS) with an estimated contract value of $600,000 over two years with three optional one-year renewals; the contract commences September 1, 2026 with anticipated award August 10, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting relationships between state pharmacy benefit programs and pharmaceutical manufacturers. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 due March 26, 2026 for generic multi-source pharmaceuticals and over-the-counter products, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with awards effective July 1, 2026.